YOUR FUTURE

Gabriella Breno is CEO of Prelios Innovation, the Prelios Group subsidiary in charge of developing and marketing BlinkS: an innovative, digital marketplace for NPE portfolio trading. Gabriella joined Prelios as Managing Director of Operations in Prelios Credit Servicing in 2014. Before joining Prelios, she developed a remarkable background in Barclays Bank PLC – Italy, where she held various leading roles from 2007 to 2013. Starting as Head of Business Planning, Development and Monitoring in the Business Department, in 2012 she first was promoted to Strategic Planning and Chief of Staff and later took charge as Head of Cards and Salary Advanced Loans. From 2001 to 2007, Gabriella worked within the Financial Services Practice for Bain and Company Italy. Throughout this period, she developed and implemented a series of strategic projects for primary Italian financial market players. Before joining Bain, Gabriella gathered significant work experience in a variety of companies, which allowed her to broaden her vision, skill-set and know-how. Amongst others, it is noteworthy to mention her employment history in Mover S.p.A. (Internet start-up in the payments industry), Gemini Consulting (strategic consultancy), Banca Commerciale Italiana and JP Morgan. Gabriella is an alumnus of the Bocconi University in Milan, where she holds a Bachelor’s Degree in Economics.

Raffaela Fede (Ascoli Piceno, 05/05/1980) is Medical Director of AstraZeneca Italy. She is an endocrinologist and has joined the company since 2018, taking on roles of increasing responsibility. She started her career in AstraZeneca as Medical Head of the Metabolic Area, a role later extended to the whole Cardiovascular, Renal and Metabolic Area (CVRM), leading the team by launching new molecules and new indications, which contributed to improve clinical practice in the relevant therapeutic areas. She was later appointed Medical Head of Respiratory and Immunology, where she was in charge of the scientific and research activities related to inhaled drugs, biologics and vaccines, and of the relations with key opinion leaders in these therapeutic areas. Since 2021 she has been leading AstraZeneca's Medical Direction in Italy, fostering the creation of new therapeutic areas, such as infectious diseases and immunology, setting the vision towards innovation but also with a strong patient-centricity, without ever losing focus on people's growth and development. Always passionate about science and research, Raffaela Fede consolidated her background starting with her studies in Medicine and Surgery at the University of Perugia, where she then specialised at the Department of Internal Medicine, Endocrine and Metabolic Unit of the Santa Maria della Misericordia Hospital, conducting clinical and research activities; She then completed a PhD in Endocrinology and Metabolic Diseases, Biosciences, Biotechnologies and Biomaterials in Vascular and Endocrine-Metabolic Diseases. After her academic experience, she joined Eli Lilly, a company where she began working in the area of metabolic and cardiovascular diseases, coordinating both clinical planning aspects and strategic ones, leading technical-scientific management activities for the launch of new molecules. She is married, has two children and lives in Milan.

Guia Ricci is a Partner in the Milan office, Core Member of the Fashion & Luxury Practice. After a Bachelor and Master's Degree cum Laude in Industrial Engineering from Politecnico di Milano, Guia gained an MBA, with Dean's Honor, from Columbia Business School with focus on Retail & Luxury Goods. She has a broad expertise in Fashion & Luxury, covering different topics and several geographies. Guia’s expertise and focus include: omnichannel, merchandising and collection structure, organizational redesign, new concept development and launch as well as consumer understanding and segmentation. Furthermore, Guia is one of the co-authors of the last 5 editions of the "True-Luxury Global Consumer Insight". An innovative research on the Luxury Consumers developed by BCG in cooperation with Fondazione Altagamma (12'000 True-Luxury consumers in top 10 countries).